Cytokinetics | CYTK - Assets


Cytokinetics reported $1.82B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Amgen USD 96.05B 409M Sep/2026
Arca Biopharma USD 1.14B 634.91M Jun/2026
Bayer EUR 113.47B 6.18B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Capricor Therapeutics USD 368.74M 42.45M Jun/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Geron USD 527.11M 8.1M Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Ligand Pharmaceuticals USD 2.24B 51.59M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 130.29B 1.23B Sep/2026